Latest news in cancer
New dosing regimen for asparaginase erwinia chrysanthemi (recombinant) is approved by FDA
Dec 2022: A new Monday-Wednesday-Friday dosing schedule for asparaginase erwinia chrysanthemi (recombinant)-rywn has been approved by the Food and Drug...
Mirvetuximab soravtansine-gynx is granted accelerated approval for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer
November 2022: For adult patients who have had one to three prior systemic treatment regimens and have folate receptor alpha (FR) positive, platinum-resistant...
Tremelimumab is approved by FDA in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancer
November 2022: The combination of tremelimumab (Imjudo, AstraZeneca Pharmaceuticals), durvalumab (Imfinzi, AstraZeneca Pharmaceuticals), and platinum-based...
Brentuximab vedotin is approved by FDA in combination with chemotherapy for pediatric patients with classical Hodgkin lymphoma
November 2022: The combination of doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide with brentuximab vedotin (Adcetris, Seagen, Inc.) has...
Cemiplimab-rwlc is approved by FDA in combination with platinum-based chemotherapy for non-small cell lung cancer
November 2022: The combination of cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) and platinum-based chemotherapy for adult patients with advanced...
Teclistamab-cqyv is approved by FDA for relapsed or refractory multiple myeloma
November 2022: The first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), was given...
Tremelimumab is approved by FDA in combination with durvalumab for unresectable hepatocellular carcinoma
November 2022: The Food and Drug Administration approved tremelimumab (Imjudo, AstraZeneca Pharmaceuticals) in combination with durvalumab for adult patients...
Cccelerated approval is granted by FDA to futibatinib for cholangiocarcinoma
November 2022: The Food and Drug Administration granted accelerated approval to futibatinib (Lytgobi, Taiho Oncology, Inc.) for adult patients with previously...
Selpercatinib is approved by FDA for locally advanced or metastatic RET fusion-positive solid tumors
November 2022: Selpercatinib (Retevmo, Eli Lilly and Company) received accelerated approval from the Food and Drug Administration to treat adult patients with...
Sodium thiosulfate is approved by FDA to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors
November 2022: In children aged one month and older with localised, non-metastatic solid tumours, the Food and Drug Administration has approved sodium...
Durvalumab is approved for locally advanced or metastatic biliary tract cancer
November 2022: For adult patients with locally advanced or metastatic biliary tract cancer, the Food and Drug Administration has approved durvalumab (Imfinzi,...
Pemigatinib is approved for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement
November 2022: Pemigatinib (Pemazyre, Incyte Corporation) has been licenced by the Food and Drug Administration for use in people with relapsed or refractory...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.